Yonsei University

Intron Biotechnology Co., Ltd

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Ho Jeong Kwon

Yeo Joon Yoon

Yeon Hee Ban

Hye Jin Jung

Shinde Pramodb

Jung Hwa Chang

Jeong Eun Kim

Gyoon Hee Han

Nam Hee Kim

Jeong Jea Seo

Chang Jin Kim

Sangmee Ahn Jo

Yong Hyo Kim

Inho Jo

Yonghyo Kim

Jeong Eun Park

György Marko-Varga

Yoon Sun Cho

Disclosed is a method for expecting and diagnosing UQCRB-related disease, and more particularly, related to a method for diagnosing a UQCRB-related disease and a cholesterol biosynthesis related disease, as well as expecting risks of post-occurrence of the UQCRB-related disease and the cholesterol biosynthesis related disease, simply by measuring an expression level of miRNA, and a kit and a biomarker composition for the method.

Method for expecting and diagnosing UQCRB-related disease

Disclosed is a angiogenesis inhibition determining method using MALDI mass spectrometry, and more particularly, relate to a method for detecting whether small molecules are bound with a target protein and for measuring a binding distribution between the small molecules and the target protein by comparing a result of MALDI mass spectrometry with a result of immunofluorescence of the small molecules, which are used as drugs, for the target protein, and for determining as angiogenesis is inhibited in a portion overlapping with a portion where the drug small molecules are present after the MALDI mass spectrometry in the cell or in the biosample including organelles and a portion where the target protein is present after immunofluorescence, as well as for detecting presence or absence and a distribution state of small molecules used as drugs in a sample by using MALDI mass spectrometry.

Small molecule detection and localization method based on MALDI imaging mass spectrometry

The present invention relates to an FK506 derivative which has reduced immunosuppressive activity but maintains nerve regeneration activity, a preparing method thereof, and a pharmaceutical composition comprising the same for preventing or treating nervous system diseases. A composition comprising 9-deoxo-prolyl-FK506, 31-O-demethyl-FK506, or 9-deoxo-31-O-demethyl-FK506 can promote nerve regeneration and has reduced immunosuppressive activity, thereby reducing side effects in the treatment of nervous system diseases.

FK506 derivative maintaining nerve regeneration activity without immunosuppressive activity, and use thereof

The present invention provides a pharmaceutical composition for inhibiting angiogenesis containing a plant-derived natural compound which can be effective for preventing or treating disorders or diseases associated with angiogenesis. The compound used as an active ingredient in the pharmaceutical composition of the present invention suppresses VEGF-induced angiogenic responses without cytotoxicity at a low concentration by inhibiting the expression of an anti-angiogenic factor (for example, VEGF), and thus remarkably improves the safety of a drug.

Pharmaceutical compositions for inhibiting angiogenesis comprising plant-derived natural compound

The present invention provides a pharmaceutical composition for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient and a method for screening an agent for preventing or treating angiogenic diseases. According to the present invention, inhibition of the NUP153 gene expression or the NUP153 activity reduces export of mRNA of a pro-angiogenic factor (VEGF, HGF and bFGF) from nucleus. In addition, inhibition of the NUP153 gene expression or the NUP153 activity has effect that angiogenesis are inhibited by inhibition of invasion and tube formation in a dose-dependent manner without showing toxicity. Therefore, the pharmaceutical composition of the present invention may be used for preventing or treating a variety of angiogenesis-related diseases, and the method for screening of the present invention may be valuably used in finding a new agent for preventing or treating angiogenic diseases.

Pharmaceutical compositions for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient

The present invention relates to a mitochondrial UQCRB mutant cell line expressing the UQCRB mutant protein. The present invention is directed to a novel research method for UQCRB activity evaluation using a novel mitochondrial UQCRB mutant cell line, and provides a method for anticancer activity evaluation, a method for angiogenesis inhibitory activity evaluation, and a method for screening a UQCRB activity inhibitor. In particular, the cell line of the present invention is a novel cell line having cell proliferative and angiogenesis inducing activities, and provides a method for screening an angiogenesis inhibitor or an anticancer material through the UQCRB activity inhibitory mechanism, and thus can be applied in the development of therapeutic agents against angiogenesis or mitochondria-mediated diseases and various cancers.

Construction of mitochondrial UQCRB mutant expressing cells and utilization of the cells for UQCRB assay system thereof

The present invention relates to a pharmaceutical composition for inhibiting angiogenesis and a novel sulfonyl amide derivative compound which can be useful for the prevention or treatment of angiogenesis-related diseases or disorders. Since the compound used as an active ingredient in the pharmaceutical composition of the invention is specifically bound to UQCRB and inhibits biological functions thereof, apoptosis is not induced and angiogenic responses are inhibited. Therefore, the compound used as an active ingredient in the pharmaceutical composition of the invention can be useful as an effective and safe angiogenesis inhibitory agent.

Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis

The present invention relates to a pharmaceutical composition for preventing or treating autophagy-related diseases, angiogenic diseases or hypermelanosis, comprising: (a) a pharmaceutically effective amount of an indatraline derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The composition of the present invention effectively induces autophagy of cells, and thus is very effective for preventing or treating autophagy-related diseases. In addition, the composition of the present invention inhibits angiogenesis through the mechanism of inhibiting angiogenesis, invasion and metastasis and inhibits melanogenesis, and thus can also be effective for preventing or treating angiogenic diseases or melanin-related diseases.

Pharmaceutical composition for preventing or treating autophagy-related diseases, angiogenic diseases or melanin-related diseases

A PTD-UQCRB fusion polypeptide, and a pharmaceutical composition for preventing and treating ischemic diseases, containing the same. The PTD-UQCRB fusion polypeptide of the present invention very effectively passes through a cell membrane to induce angiogenesis and does not cause cytotoxicity, and is thus useful for preventing and treating ischemic diseases.

PTD-UQCRB fusion polypeptide, and pharmaceutical composition for preventing and treating ischemic diseases, containing same

Provided is a pharmaceutical composition for inhibiting angiogenesis, comprising a therapeutically effective amount of a compound represented by Formula 1: (I) wherein R1 through R13 and X are as defined in the specification. Compounds used as an active ingredient in the pharmaceutical composition of the present invention bind to QP-C to provide effective prevention of angiogenesis and can be effectively used for prevention and/or treatment of angiogenesis-related diseases or disorders. Further, the active compounds of the present invention inhibit biological functions of QP-C, which consequently leads to inhibition of angiogenic responses without the risk of cellular apoptosis, thus significantly improving safety of the drug. 

Pharmaceutical compositions for inhibiting angiogenesis

The present invention relates to a novel protein inhibiting &#x3b2; amyloid aggregation and a strain producing the protein, more precisely, to a novel protein inhibiting &#x3b2; amyloid aggregation, a gene coding the protein, asp. strain producing the protein and a therapeutic agent for neurodegenerative disorders containing the protein as an effective ingredient. The therapeutic agent of the present invention containing the protein inhibiting &#x3b2; amyloid aggregation as an effective ingredient can be effectively used for the prevention and the treatment of neurodegenerative disorders like Alzheimer's disease.

Growing community of inventors

Seoul, South Korea

Ho Jeong Kwon